Bristol-Myers
Squibb Company (NYSE: BMY) announced that it has appointed
scientific and business thought-leader, Saurabh Saha, M.D., Ph.D., as
senior vice president and global head of translational medicine in the
company’s R&D organization, effective today.
“Enhancing our translational medicine capability is critical to
achieving our mission, and we are excited to add Dr. Saha’s broad
leadership experience and deep scientific expertise to our team,” said
Tom Lynch, M.D., executive vice president and chief scientific officer
of Bristol-Myers Squibb. “Dr. Saha will lead translational research
across our therapeutic areas of focus to ensure we have the best
understanding of disease and asset-specific biology so we can deliver
the right drug to the right patient at the right time.”
Dr. Saha said, “Throughout my career, I have had a passion for
developing translational research strategies across disease areas,
including oncology and immunology. I look forward to working with Tom
and the rest of the R&D organization to advance Bristol-Myers Squibb’s
industry-leading pipeline in a way that pushes the boundaries of science
and enables us to rapidly deliver innovative medicines to patients with
even greater precision.”
Dr. Saha will initially be based at the company’s Waltham, Mass research
site until its new state-of-the-art research site in Cambridge, Mass
opens in the fourth quarter of 2018.
About Dr. Saurabh Saha
Dr. Saha’s extensive research experience includes leading groundbreaking
translational research and implementing innovative drug discovery
strategies that have resulted in the discovery and development of two
first-in-class cancer therapies and the pioneering of new approaches for
unmet medical needs across therapeutic areas and clinical modalities.
Prior to joining Bristol-Myers Squibb, Dr. Saha was a venture partner at
Atlas Venture where he held leadership positions with many of its
portfolio biotech companies, including as chief medical officer of
Synlogic, and as chief executive officer of Delinia until its sale to
Celgene in early 2017. In 2008, Dr. Saha established the translational
research and development organization BioMed Valley Discoveries where he
served as chief scientific officer and later president, and was
responsible for leading the development and demonstrating human
effectiveness of novel cancer drugs for refractory and resistant
disease, including an ERK inhibitor and a bacteriolytic immunotherapy.
Earlier in his career, Dr. Saha was a consultant in the pharmaceutical
practice at McKinsey and Company and subsequently appointed director and
head of the New Indications Discovery Unit at Novartis. Dr. Saha is on
the editorial boards of numerous prestigious medical journals and is an
associate member and global clinical scholar at Harvard Medical School.
Dr. Saha holds an M.D. and Ph.D. in cancer genetics from The Johns
Hopkins School of Medicine, where he completed his graduate studies in
Bert Vogelstein’s lab. He is an alumnus of Harvard Business School and
Oxford University, studying general management and biophysics
respectively. Dr. Saha completed his undergraduate studies in
biochemistry from the California Institute of Technology (Caltech).
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission
is to discover, develop and deliver innovative medicines that help
patients prevail over serious diseases. For more information about
Bristol-Myers Squibb, visit us at BMS.com
or follow us on LinkedIn,
Twitter,
YouTube
and Facebook.